Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“CTTQ”), a subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”), has received advice from Baker McKenzie regarding an exclusive license agreement with Sanofi S.A. (“Sanofi”) for rovadicitinib, a novel, potent, first-in-class oral small molecule JAK/ROCK inhibitor.